カテーテル関連血流感染市場- 世界の産業規模、シェア、動向、機会、予測、治療タイプ別、感染源別、流通チャネル別、地域別、競合別、2020～2030年

カテーテル関連血流感染の世界市場規模は2024年に16億2,000万米ドルで、予測期間中のCAGRは5.62%で2030年には22億5,000万米ドルに達すると予測されています。

カテーテル関連血流感染の世界市場は、院内感染、特に中心静脈カテーテルに関連する感染症が増加していることが主要要因です。カテーテル関連の血流感染は、中心静脈カテーテル使用による最も頻度の高い深刻な合併症の1つであり、重大な罹患率、死亡率、医療コストにつながります。特に化学療法などの治療を受けている免疫不全患者のような高リスク群における血流感染症の発生率の上昇が、市場の成長をさらに後押ししています。カテーテル関連血流感染症の治療を複雑にする抗生物質耐性に対する懸念の高まりは、先進的診断ツールや感染予防戦略に対する需要の高まりにつながっています。こうした複合的な要因が、世界のカテーテル関連血流感染市場の拡大に寄与しています。

市場概要
予測期間	2026～2030年
市場規模：2024年	16億2,000万米ドル
市場規模：2030年	22億5,000万米ドル
CAGR：2025～2030年	5.62%
急成長セグメント	抗菌剤
最大市場	北米

市場促進要因

院内感染の増加

主要市場課題

先進的感染予防技術の高コスト

主要市場動向

カテーテル材料の技術進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のカテーテル関連血流感染市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 治療タイプ別（抗菌剤、抗生物質ロック療法）
  • 感染源別（コアグラーゼ陰性ブドウ球菌、黄色ブドウ球菌、腸内グラム陰性桿菌、酵母、腸球菌と連鎖球菌、緑膿菌、その他）
  • 流通チャネル別（病院薬局、小売薬局、オンライン薬局）
  • 地域別
  • 企業別（2024年）
• 市場マップ

第6章 北米のカテーテル関連血流感染市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州のカテーテル関連血流感染市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋のカテーテル関連血流感染市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米のカテーテル関連血流感染市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのカテーテル関連血流感染市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収（該当する場合）
• 製品の発売（該当する場合）

第13章 ポーターのファイブフォース分析

• 産業内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Teva Pharmaceutical Industries Ltd.
• SteriMax Inc.
• Sanofi S.A.
• Pfizer Inc.
• Novartis AG
• Merck & Co., Inc.
• GSK plc
• Fresenius SE & Co. KGaA
• Eli Lilly and Company
• Aurobindo Pharma Limited

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Catheter Related Bloodstream Infection Market was valued at USD 1.62 Billion in 2024 and is expected to reach USD 2.25 Billion by 2030 with a CAGR of 5.62% during the forecast period. The global Catheter Related Bloodstream Infection market is primarily driven by the increasing prevalence of hospital-acquired infections, particularly those associated with central venous catheters. Catheter related bloodstream infections are among the most frequent and serious complications of central venous catheter use, leading to significant morbidity, mortality, and healthcare costs. The rising incidence of bloodstream infections, especially in high-risk groups like immunocompromised patients undergoing treatments such as chemotherapy, further fuels market growth. The growing concern over antibiotic resistance, which complicates the treatment of catheter related bloodstream infections, has led to a rising demand for advanced diagnostic tools and infection prevention strategies. These combined factors are contributing to the expansion of the global Catheter Related Bloodstream Infection market.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 1.62 Billion
Market Size 2030	USD 2.25 Billion
CAGR 2025-2030	5.62%
Fastest Growing Segment	Anti-microbial Agents
Largest Market	North America

Key Market Drivers

Increasing Prevalence of Hospital-Acquired Infections

Hospital-acquired infections (HAIs) are one of the most significant health concerns in medical settings globally. Catheter-related bloodstream infections (CRBSIs) are one of the leading types of HAIs, and their rising prevalence plays a substantial role in driving the growth of the global Catheter Related Bloodstream Infection market. These infections occur when pathogens enter the bloodstream through central venous catheters, a common medical device used for administering medications, fluids, and nutrients to critically ill patients. The growing number of patients requiring invasive procedures such as surgeries, dialysis, and long-term intravenous treatments leads to an increase in catheter usage, thus elevating the risk of CRBSIs. This, in turn, results in an increased demand for effective infection prevention and diagnostic solutions. According to WHO, On average, approximately 1 in 10 patients experiences healthcare-associated infections (HAIs); however, the incidence is notably higher in low- and middle-income countries, as well as among high-risk patients, such as those in intensive care units. According to a 2023 study by Balasubramanian et al., around 136 million cases of healthcare-associated antibiotic-resistant infections occur globally each year. In Europe, the impact of the six most common HAIs was found to be twice as significant as the combined burden of 32 other infectious diseases, in terms of disability and premature mortality. Additionally, it was estimated that 63.5% of infections caused by antibiotic-resistant bacteria are associated with healthcare settings.

Key Market Challenges

High Cost of Advanced Infection Prevention Technologies

One of the significant challenges in the global Catheter Related Bloodstream Infection market is the high cost of advanced infection prevention technologies. While innovative solutions such as antimicrobial-coated catheters, rapid diagnostic tools, and biofilm-resistant materials have proven effective in reducing infection rates, these technologies often come with a premium price. This cost barrier can be a challenge, especially in low-resource healthcare settings or emerging markets where budget constraints are a significant concern. Hospitals and healthcare providers may be hesitant to adopt these advanced solutions if they face financial limitations, despite the long-term benefits in terms of improved patient outcomes and reduced healthcare costs. The cost of training healthcare staff to effectively use these advanced technologies and maintain infection control protocols further compounds the financial burden on healthcare systems, making it difficult for some institutions to fully embrace these innovations.

Key Market Trends

Technological Advancements in Catheter Materials

Innovations in catheter design and material science are also contributing to the growth of the catheter-related bloodstream infection market. One significant development has been the introduction of antimicrobial-coated catheters, which are designed to reduce the risk of infection by inhibiting the growth of bacteria and other pathogens on the surface of the catheter. These catheters have been shown to significantly decrease the incidence of catheter-related bloodstream infections, especially in high-risk patient populations. In January 2025, Autonomix Medical, Inc. announced that it has achieved "design lock" for its Application Specific Integrated Circuits (ASIC) microchip. This milestone follows the successful completion of in vivo preclinical testing and extensive bench testing, marking continued progress toward the Company's U.S. pivotal trial.

The development of biofilm-resistant materials, which prevent the formation of bacterial biofilms on catheter surfaces, is further enhancing the safety and efficacy of catheters. As these technologies continue to advance, the demand for these more sophisticated catheter products is likely to grow, driving market expansion.

Key Market Players

• Teva Pharmaceutical Industries Ltd.
• SteriMax Inc.
• Sanofi S.A.
• Pfizer Inc.
• Novartis AG
• Merck & Co., Inc.
• GSK plc
• Fresenius SE & Co. KGaA
• Eli Lilly and Company
• Aurobindo Pharma Limited

Report Scope:

In this report, the Global Catheter Related Bloodstream Infection Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Catheter Related Bloodstream Infection Market, By Treatment Type:

• Anti-microbial Agents
• Antibiotic Lock Therapy

Catheter Related Bloodstream Infection Market, By Source of Infection:

• Coagulase-negative Staphylococcus
• S. Aureus
• Enteric Gram-negative Bacilli
• Yeasts
• Enterococci & Streptococci
• Pseudomonas
• Others

Catheter Related Bloodstream Infection Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Catheter Related Bloodstream Infection Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Catheter Related Bloodstream Infection Market.

Available Customizations:

Global Catheter Related Bloodstream Infection market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Catheter Related Bloodstream Infection Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment Type (Anti-microbial Agents and Antibiotic Lock Therapy)
  • 5.2.2. By Source of Infection (Coagulase-negative Staphylococcus, S. Aureus, Enteric Gram-negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas, and Others)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Catheter Related Bloodstream Infection Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment Type
  • 6.2.2. By Source of Infection
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Catheter Related Bloodstream Infection Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment Type
      • 6.3.1.2.2. By Source of Infection
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Catheter Related Bloodstream Infection Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment Type
      • 6.3.2.2.2. By Source of Infection
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Catheter Related Bloodstream Infection Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment Type
      • 6.3.3.2.2. By Source of Infection
      • 6.3.3.2.3. By Distribution Channel

7. Europe Catheter Related Bloodstream Infection Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment Type
  • 7.2.2. By Source of Infection
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Catheter Related Bloodstream Infection Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment Type
      • 7.3.1.2.2. By Source of Infection
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. United Kingdom Catheter Related Bloodstream Infection Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment Type
      • 7.3.2.2.2. By Source of Infection
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Italy Catheter Related Bloodstream Infection Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment Type
      • 7.3.3.2.2. By Source of Infection
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. France Catheter Related Bloodstream Infection Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment Type
      • 7.3.4.2.2. By Source of Infection
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Catheter Related Bloodstream Infection Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment Type
      • 7.3.5.2.2. By Source of Infection
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Catheter Related Bloodstream Infection Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment Type
  • 8.2.2. By Source of Infection
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Catheter Related Bloodstream Infection Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment Type
      • 8.3.1.2.2. By Source of Infection
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Catheter Related Bloodstream Infection Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment Type
      • 8.3.2.2.2. By Source of Infection
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Catheter Related Bloodstream Infection Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment Type
      • 8.3.3.2.2. By Source of Infection
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Catheter Related Bloodstream Infection Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment Type
      • 8.3.4.2.2. By Source of Infection
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Catheter Related Bloodstream Infection Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment Type
      • 8.3.5.2.2. By Source of Infection
      • 8.3.5.2.3. By Distribution Channel

9. South America Catheter Related Bloodstream Infection Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment Type
  • 9.2.2. By Source of Infection
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Catheter Related Bloodstream Infection Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment Type
      • 9.3.1.2.2. By Source of Infection
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Catheter Related Bloodstream Infection Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment Type
      • 9.3.2.2.2. By Source of Infection
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Catheter Related Bloodstream Infection Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment Type
      • 9.3.3.2.2. By Source of Infection
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Catheter Related Bloodstream Infection Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment Type
  • 10.2.2. By Source of Infection
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Catheter Related Bloodstream Infection Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment Type
      • 10.3.1.2.2. By Source of Infection
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Catheter Related Bloodstream Infection Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment Type
      • 10.3.2.2.2. By Source of Infection
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Catheter Related Bloodstream Infection Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment Type
      • 10.3.3.2.2. By Source of Infection
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Teva Pharmaceutical Industries Ltd.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. SteriMax Inc.
• 14.3. Sanofi S.A.
• 14.4. Pfizer Inc.
• 14.5. Novartis AG
• 14.6. Merck & Co., Inc.
• 14.7. GSK plc
• 14.8. Fresenius SE & Co. KGaA
• 14.9. Eli Lilly and Company
• 14.10. Aurobindo Pharma Limited

15. Strategic Recommendations

16. About Us & Disclaimer